BayBiotech.NET
As per definition of National Technology Initiative, nanotechnology is the understanding and control of matter at dimensions between approximately 1 and 100 nanometers. Encompassing nanoscale science, engineering, and technology, nanotechnology involves imaging, measuring, modeling, and manipulating matter at this length scale. According to NTIG at this scale unusual physical, chemical, and biological properties can emerge in materials and the properties may differ in important ways from the properties of bulk materials and single atoms or molecules.
Recognizing a great potential for this technology for drug delivery/ device in medicine, in July 2007 FDA issued a press release outlining the regulatory challenges that the implementation of the technology will have for the agency and geared up towards developing guidance as well as regulations to address the benefits and risks of drugs and devices using nanotechnology. As it is obvious, development and Implementation of nanotechnology in medical field will require multiple expertise (device, drug, engineering and more) agency has formed a nanotechnology interest group (NTIG) to facilitate the regulation of nanotechnology products. NTIG is made up of representatives from multiple centers (so far FDA and 22 other federal agencies are members) and meets quarterly to ensure there is effective communication between the Centers. Most of the Centers also have working groups that establish the network between their different components. To find out more about the national Nanotechnology Initiative visit http://www.nano.gov/.
For more information on the agencies outlook on Nanotechnology products if you have an interest in developing a drug or device at nanoscale visit the link: http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/default.htm
As per definition of National Technology Initiative, nanotechnology is the understanding and control of matter at dimensions between approximately 1 and 100 nanometers. Encompassing nanoscale science, engineering, and technology, nanotechnology involves imaging, measuring, modeling, and manipulating matter at this length scale. According to NTIG at this scale unusual physical, chemical, and biological properties can emerge in materials and the properties may differ in important ways from the properties of bulk materials and single atoms or molecules.
Recognizing a great potential for this technology for drug delivery/ device in medicine, in July 2007 FDA issued a press release outlining the regulatory challenges that the implementation of the technology will have for the agency and geared up towards developing guidance as well as regulations to address the benefits and risks of drugs and devices using nanotechnology. As it is obvious, development and Implementation of nanotechnology in medical field will require multiple expertise (device, drug, engineering and more) agency has formed a nanotechnology interest group (NTIG) to facilitate the regulation of nanotechnology products. NTIG is made up of representatives from multiple centers (so far FDA and 22 other federal agencies are members) and meets quarterly to ensure there is effective communication between the Centers. Most of the Centers also have working groups that establish the network between their different components. To find out more about the national Nanotechnology Initiative visit http://www.nano.gov/.
For more information on the agencies outlook on Nanotechnology products if you have an interest in developing a drug or device at nanoscale visit the link: http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/default.htm
Comments
Post a Comment